MedTrace Logo

Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC

NCT04611373 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-11-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.

Conditions

Interventions

DRUG

Acetazolamide Levamisole

Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-12-01
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04611373 on ClinicalTrials.gov